Consensus Madrigal Pharmaceuticals, Inc.

Stocks

MDGL

US5588681057

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 24/10/2026 am IST			5-day change	1st Jan Change
434.24 ^USD	-4.21%		-3.45%	-25.43%

19/10	BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says	MT
19/10	BofA Securities Adjusts Price Target on Madrigal Pharmaceuticals to $533 From $543, Maintains Neutral Rating	MT

Evolution of the Average Target: Madrigal Pharmaceuticals, Inc.

Evolution of the Target Price: Madrigal Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Madrigal Pharmaceuticals, Inc.

5c0916e8f5eb0.7LoS_o3v2azs8g4g8QAypmBEPLqZbNvbqJ4ZCOhKNPY.hetEqP2BsZ-6hn5vq1JayiMKavboK-6Lwc4oOdE4eaWFin_Px4Xv86eTTw~7a521ef17f9d12824e67c8ab5a7de895

Analysts' recommendations: Madrigal Pharmaceuticals, Inc.

19/10	BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says	MT
19/10	BofA Securities Adjusts Price Target on Madrigal Pharmaceuticals to $533 From $543, Maintains Neutral Rating	MT
24/09	Analyst recommendations: Dropbox, Etsy, Meta Platforms, Okta, Rollins…
23/09	Citigroup Initiates Madrigal Pharmaceuticals at Buy With $725 Price Target	MT
27/07	Wells Fargo Initiates Madrigal Pharmaceuticals at Overweight With $685 Price Target	MT
22/07	BofA Securities Adjusts Price Target on Madrigal Pharmaceuticals to $553 From $542	MT
14/07	Madrigal Pharmaceuticals' Three New Patents Support Patent Extension Into 2045, Truist Says	MT
11/06	BofA Securities Adjusts Madrigal Pharmaceuticals Price Target to $542 From $550	MT
13/05	Truist Raises Price Target on Madrigal Pharmaceuticals to $709 From $640, Keeps Buy Rating	MT
02/02	Biotech Inventiva's 50% surge shows investor optimism over liver disease drug	RE
28/01	Barclays Initiates Coverage on Madrigal Pharmaceuticals With Overweight Rating, $964 Price Target	MT
11/12	B. Riley Raises Price Target on Madrigal Pharmaceuticals to $670 From $560, Keeps Buy Rating	MT
20/11	Oppenheimer Adjusts Price Target on Madrigal Pharmaceuticals to $650 From $600, Maintains Outperform Rating	MT
19/11	Truist Raises Price Target on Madrigal Pharmaceuticals to $640 From $580, Keeps Buy Rating	MT
06/11	Madrigal Pharmaceuticals Shares Rise After Cantor Fitzgerald Upgrade	MT
05/11	Cantor Fitzgerald Upgrades Madrigal Pharmaceuticals to Overweight From Neutral	MT
03/11	Madrigal Pharmaceuticals' Liver Disease Treatment Rezdiffra Outperforms Early Cautious Outlook, BofA Says	MT
03/11	BofA Upgrades Madrigal Pharmaceuticals to Neutral From Underperform, Price Target is $445	MT
28/25/28	Madrigal Pharmaceuticals, Inc. to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025	CI
29/25/29	B. Riley Raises Price Target on Madrigal Pharmaceuticals to $560 From $460, Keeps Buy Rating	MT
12/25/12	UBS Adjusts Price Target on Madrigal Pharmaceuticals to $523 From $458, Maintains Buy Rating	MT
05/25/05	Madrigal Pharma's Q2 sales surge on Rezdiffra demand	RE
02/25/02	UBS Adjusts Madrigal Pharmaceuticals Price Target to $458 From $441, Maintains Buy Rating	MT
28/25/28	B. Riley Upgrades Madrigal Pharmaceuticals to Buy From Neutral, Raises Price Target to $422 From $236	MT
27/25/27	Madrigal Pharmaceuticals Shares Still Undervalued Amid Long-Term Growth Potential, UBS Says	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	MADRIGAL PHARMACEUTICALS, INC.					+57.8%
	WUXI APPTEC CO., LTD.					+32.59%
	ARGENX SE					+28.09%
	LONZA GROUP AG					+10.26%
	IQVIA HOLDINGS INC.					+8.34%
	BEONE MEDICINES AG					+15.58%
	REVOLUTION MEDICINES, INC.					+38.43%
	CELLTRION, INC.					+38.53%
	GENMAB A/S					+4.99%
	WUXI BIOLOGICS (CAYMAN) INC.					+31.23%
	Average					+26.58%
	Weighted average by Cap.					+24.23%